Searched for: author%3A%22Jongsma%2C+M.J.%22
(1 - 9 of 9)
document
Verhave, P.S. (author), Jongsma, M.J. (author), van den Berg, R.M. (author), Vanwersch, R.A.P. (author), Smit, A.B. (author), Philippens, I.H.C.H.M. (author)
The present study evaluates neuroprotection in a marmoset MPTP (1-methyl-1,2,3,6-tetrahydropyridine) model representing early Parkinson's disease (PD). The anti-glutamatergic compound riluzole is used as a model compound for neuroprotection. The compound is one of the few protective compounds used in the clinic for a neurodegenerative disorder....
article 2012
document
Verhave, P.S. (author), Jongsma, M.J. (author), van den Berg, R.M. (author), Vis, J.C. (author), Vanwersch, R.A.P. (author), Smit, A.B. (author), van Someren, E.J.W. (author), Philippens, I.H.C.H.M. (author)
Study Objectives: Sleep problems are a common phenomenon in most neurological and psychiatric diseases. In Parkinson disease (PD), for instance, sleep problems may be the most common and burdensome non-motor symptoms in addition to the well-described classical motor symptoms. Since sleep disturbances generally become apparent in the disease...
article 2011
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Vanwersch, R.A.P. (author), Jongsma, M.J. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
Current therapies for Parkinson's disease (PD) like l-dopa and dopamine (DA) agonists have declined efficacy after long term use. Therefore, research towards supplementary or alternative medication is needed. The implementation in PD can be expedited by application of compounds already used in the clinic. In this study the therapeutic effects of...
article 2008
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
article 2008
document
TNO Defensie en Veiligheid (author), Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Joosen, M.J.A. (author), Bouwman, G. (author), Vanwersch, R.A.P. (author)
Compounds with another mechanism of action than enzyme inhibition alone were tested in their capability to counteract or prevent incapacitation and lethality after 2xLD50 soman when used as a pretreatment or as a post-intoxication therapy in guinea pigs. To increase the validity of extrapolating data to man, crucial experiments were performed in...
conference paper 2007
document
Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Vanwersch, R.A. (author), TNO Defensie en Veiligheid (author)
The efficacy against lethality and post-intoxication incapacitation after 2x LD50 soman of different subacute pretreatment scenarios of 12 days was tested with or without post-intoxication therapy in guinea pigs. These pretreatment regimes were 1) the currently used pyridostigmine (PYR, 0.04 mg/kg/hr), 2) the combination of physostigmine (PHY, 0...
conference paper 2006
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Vanwersch, R.A.P. (author), Jongsma, M.J. (author), van der Gugten, J. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
The vigilance-enhancing agent modafinil has neuroprotective properties: it prevents striatal ischemic injury, nigrostriatal pathway deterioration after partial transsection and intoxication with 1-methyl-1,2,3,6-tetrahydropyridine. The present study determines the protective effects of modafinil in the marmoset 1-methyl-1,2,3,6...
article 2006
document
TNO Defensie en Veiligheid (author), van Vliet, S.A.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Olivier, B. (author), Philippens, I.H.C.H.M. (author)
Rationale: Modafinil is increasingly used in sleep disturbances in general and in neurodegenerative diseases and is recently being used in healthy people for attention control. However, the application of modafinil is possibly not only restricted to alertness enhancing effects. More insight in this compound may lead to new applications. Not all...
article 2006
document
Philippens, I.H.C.H.M. (author), Jongsma, M.J. (author), Vanwersch, R.A.P. (author), Prins Maurits Laboratorium TNO (author)
The efficacy against lethality and post-intoxication incapacitation after 2x LD50 soman of different subacute pretreatment scenarios of 12 days was tested with or without post-intoxication therapy in guinea pigs. These pretreatment regimes were 1) the currently used pretreatment with pyridostigmine (PYR, 0.04 mg/kg/hr), 2) the combination of...
conference paper 2004
Searched for: author%3A%22Jongsma%2C+M.J.%22
(1 - 9 of 9)